Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 17, 2023 08:00 ET | Source: Imbria Pharmaceuticals Inc.

Imbria Pharmaceuticals to Participate in SVB Securities Biopharma Private Company Connect

BOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced...
January 09, 2023 08:00 ET | Source: Imbria Pharmaceuticals Inc.

Imbria Enrolls First Patient in the Phase 2 IMPROVE-DiCE Clinical Trial Evaluating Ninerafaxstat in Patients with Heart Failure with Preserved Ejection Fraction

BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced...
December 05, 2022 08:00 ET | Source: Imbria Pharmaceuticals Inc.

Ninerafaxstat Showcased at the 19th Annual Global Cardio Vascular Clinical Trialists (CVCT) Forum with Focus on the Potential in Non-obstructive Hypertrophic Cardiomyopathy

BOSTON, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced...
October 10, 2022 08:00 ET | Source: Imbria Pharmaceuticals Inc.

Imbria Pharmaceuticals to Participate in BMO’s Fall Private Company Showcase

BOSTON, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced...
September 15, 2022 08:00 ET | Source: Imbria Pharmaceuticals Inc.

Imbria Pharmaceuticals to Participate in the UBS Biotechnology Private Company Virtual Symposium

BOSTON, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced...
August 26, 2022 08:15 ET | Source: Imbria Pharmaceuticals Inc.

Imbria Presents Positive Clinical Data for Ninerafaxstat from IMPROVE-DiCE at the European Society of Cardiology Congress 2022

BOSTON, Mass., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today...
August 22, 2022 08:00 ET | Source: Imbria Pharmaceuticals Inc.

Imbria Pharmaceuticals to Present Phase 2a Data from the Ninerafaxstat Program at the European Society of Cardiology Congress 2022

BOSTON, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardio-metabolic company developing novel therapies designed to enhance cellular energetics, today...

keyboard_arrow_left Previous Page